Aurobindo Pharma LTD

BSE: 524804 NSE: AUROPHARMA
Aurobindo Pharma LTD - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
CIN L24239TG1986PLC015190 Incorporated 26 December 1986 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Listed - NSE: AUROPHARMA · BSE: 524804 Public Limited Company pharma
Data last updated
Market Cap
₹96,479 Cr
AUROPHARMA · NSE
Share Price
₹1,676.80
+0.29% today
Revenue
₹33,653 Cr
FY 2025-26 · +6.8% YoY
EBITDA
₹6,780 Cr
Margin 20.1%
Net Profit
₹3,563 Cr
FY 2025-26 · +3.2% YoY
P/E (TTM)
25.4x
P/B 2.5x
ROE
9.9%
ROCE 12.4%
Debt / Equity
0.23
Interest cover 7.7x

About Aurobindo Pharma LTD

Data last updated:

Aurobindo Pharma LTD is a public limited company based in Hyderabad, Telangana, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 26 December 1986, the company has been in operation for over 40 years.

Registered with ROC Hyderabad under CIN L24239TG1986PLC015190. Listed on BSE: 524804 and NSE: AUROPHARMA.

Capital: an authorised share capital of ₹666.4 Cr and a paid-up capital of ₹57.54 Cr. Formerly known as Aurobindo Pharma Pvt Ltd. It is led by directors including Girish Paman Vanvari and Venkata Ramprasad Reddy Penaka.

Last AGM: 10 September 2025. Financial statements filed for year ended 31 March 2025. Office: Plot No.2 Maithrivihar Behind Maithri Vanam Ameerpet, Hyderabad, Telangana, India – 500038.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹33,653 Cr, a growth of 6.08% compared to the previous year. The net worth stands at ₹37,896 Cr (up 16.05% YoY). Total assets are valued at ₹47,134 Cr (up 14.23% YoY).

The company has a workforce of approximately 15,925 employees as per the latest available data. Its group structure includes 17 subsidiaries and 2 joint ventures.

The company is associated with 3 brands - Auronext Pharma, Aurobindo Pharma, Tergene Biotech. As per MCA filings, the company has open charges of ₹2,000 Cr and satisfied charges of ₹4,387.54 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website aurobindo.com.

Company Details of Aurobindo Pharma LTD
CIN L24239TG1986PLC015190
Registration Number 015190
Incorporation Date 26 December 1986
ROC Hyderabad
Listing Status Listed (BSE: 524804, NSE: AUROPHARMA)
Company Status Active
Date of Last AGM 10 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Nityananda Reddy Kambam Managing Director Madan Mohan Reddy Mettu Whole-Time Director Girish Paman Vanvari Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    aurobindo.com
  • Social Media
  • Registered Address
    Plot No.2 Maithrivihar Behind Maithri Vanam Ameerpet, Hyderabad, Telangana, India – 500038
  • Industry
    Pharma, Drug Formulation & Development
Company report
Aurobindo Pharma LTD - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Aurobindo Pharma LTD report

Financials, compliance, directors, charges, ownership and filings for Aurobindo Pharma LTD in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Aurobindo Pharma

Aurobindo Pharma has one previous CIN (Corporate Identification Number): L24239AP1986PLC015190. The current CIN is L24239TG1986PLC015190, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24239TG1986PLC015190Current
L24239AP1986PLC015190Previous

Associated Brands with Aurobindo Pharma

Aurobindo Pharma operates multiple associated brands including Auronext Pharma, Aurobindo Pharma, and Tergene Biotech. Each brand links to its own profile.

BrandDescriptionWebsite
Aurobindo Pharma
Generic biocatalytic solutions are provided for pharmaceutical applications.aurobindo.com
Tergene Biotech
Bio-conjugate technologies for bacterial vaccines and conjugates are developed.tergene.com
Auronext Pharma
Offers comprehensive outsourced API production services for the pharmaceutical industry.auronext.com

Competitors & Alternatives of Aurobindo Pharma

Brands and companies operating in the same space as Aurobindo Pharma LTD include Laurus Labs, Biological E, Concord Biotech and 7 more.

CompetitorDescriptionLocationFounded
Laurus Labs Laurus Labs Pharmaceutical and biotechnology companyHyderabad, India, India2005
Biological E Biological E Vaccines and therapeutics for multiple diseases are developed and marketed.Hyderabad, India, India1953
Concord Biotech Concord Biotech APIs and enzymes are manufactured through fermentation by the CDMO.Ahmedabad, India, India2000
Symbiotec Symbiotec Non-sterile steroid hormone-based APIs and intermediates are manufactured.Indore, India, India2002
BDR Pharmaceuticals Internationals BDR Pharmaceuticals Internationals APIs and finished products are developed and manufactured.Mumbai, India, India2003
Insmed Insmed Developer of small molecule inhibitors for rare lung diseasesBridgewater, United States, United States1999
Vaxart Vaxart Developer of therapeutic solutions for treating multiple infectious diseasesSan Francisco, United States, United States2004
Almac Group Almac Group Integrated CDMO services for biopharma R&D and manufacturing are offered.Craigavon, United Kingdom, United Kingdom2001
Beijing Biostar Technologies Beijing Biostar Technologies APIs, intermediates, and biochemical reagents are developed and manufactured.Beijing, China, China2002
Indoco Remedies Indoco Remedies APIs manufacturing and formulation services are provided in therapeutic segments.Mumbai, India, India1947

Business Activity of Aurobindo Pharma

The main business activity of Aurobindo Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group CodeDescription of Main ActivityBusiness Activity CodeDescription of Business ActivityTurnover Percentage
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical productsLocked
Premium access

Business activity turnover details for Aurobindo Pharma LTD

Turnover share and past changes in activity are in the company report.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Aurobindo Pharma

Aurobindo Pharma LTD is audited by Deloitte Haskins & Sells for the financial year 2024.

NameStatusAppointment DateCessation Date
Deloitte Haskins & SellsLockedLockedLocked
Premium access

Complete auditor history for Aurobindo Pharma LTD

Appointment and cessation dates and past auditor changes are in the company report.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Aurobindo Pharma LTD

Aurobindo Pharma has 9 current directors and 22 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Girish Paman Vanvari
Also directs: Transaction Square LLP, Transaction Square Consultancy LLP, Himadri Speciality Chemical Limited and 5 more
Director05 Nov 20205 Years 10 MonthsCurrent
Venkata Ramprasad Reddy Penaka
Also directs: Penaka Pharma (India) Private Limited, RPR Sons Advisors Private Limited
Director30 Dec 199233 Years 9 MonthsCurrent
Madan Mohan Reddy Mettu
Also directs: MSS Packaging Industries LLP, Engenra Biologics Private Limited, Curateq Biologics Private Limited and 5 more
Whole-Time Director01 Jan 201313 Years 9 MonthsCurrent
Sarath Chandra Reddy Penaka
Also directs: Aurobindo Pharma Foundation, Sarath Penaka Enterprises LLP, Naqsh Global Ventures LLP and 4 more
Director27 Sep 200719 Years 0 MonthsCurrent
Nityananda Reddy Kambam
Also directs: Aurobindo Antibiotics Private Limited, Apl Healthcare Limited, Apitoria Pharma Private Limited and 5 more
Managing Director30 Dec 199233 Years 9 MonthsCurrent
Santanu Mukherjee
Also directs: Apitoria Pharma Private Limited, Suven Life Sciences Limited, Sumedha Fiscal Services LTD and 4 more
Director09 Feb 20233 Years 7 MonthsCurrent
Showing 6 of 9 current directors. View all directors

Financials of Aurobindo Pharma LTD FY 2025-26 filings available

Aurobindo Pharma LTD reported revenue of ₹33,653 Cr (up 6.08% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹33,653 Cr
+6.1% YoY
EBITDA
₹6,780 Cr
+3.5% YoY
Profit After Tax
₹3,563 Cr
+3.2% YoY
Net Worth
₹37,896 Cr
+16.0% YoY
Total Assets
₹47,134 Cr
+14.2% YoY
Total Debt
₹8,068 Cr
-2.3% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue33,65331,72429,00224,85523,45524,77523,099
Revenue growth+6.8%+7.7%+10.5%+9.3%-3.0%+9.1%+16.4%
EBITDA6,7806,5515,6343,7074,1124,8434,823
EBITDA margin+20.2%+20.7%+19.4%+14.9%+17.5%+19.6%+20.9%
Profit before tax5,1125,0664,3802,6123,3737,3443,743
Net profit3,5633,4533,2731,9202,7573,4102,865
Net profit margin+10.6%+10.9%+11.3%+7.7%+11.8%+13.8%+12.4%
EPS (₹)60.3460.0254.1632.9045.2091.0548.56
Balance sheet
Total assets47,13441,26136,77632,35227,63827,51922,813
Net worth37,89632,65629,84326,84024,57621,93016,825
Total debt8,0688,2616,6485,2862,8515,3395,826
Cash & bank9,8708,2356,2786,0844,1905,4742,842
Net working capital20,90018,94215,78214,16111,87113,90310,590
Cash flow
Cash from operations5,5263,9252,4352,3875,0163,3294,381
Cash from investing(2,630)(1,866)(4,242)(3,971)(3,211)597(1,563)
Cash from financing(1,269)1208001,814(2,969)(1,365)(1,947)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue9,1508,8538,6468,2867,8688,3827,9797,796
Revenue growth (YoY)+16.9%+4.4%+9.0%+7.7%+4.5%+11.9%+8.6%+6.9%
Other income264117188122107135159136
EBITDA1,8391,7501,7081,6781,6031,7601,5781,566
EBITDA margin+20.2%+20.0%+19.9%+20.4%+20.6%+21.0%+20.0%+20.5%
Depreciation487479465429406444419382
Interest10298.2192.7795.2497.75115118113
Profit before tax1,5151,2911,3391,2761,2071,3351,2001,207
Tax483370429428383432354391
Net profit1,032921910848824903846817
EPS (₹)17.8615.8615.6714.6114.2015.5614.5614.00
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue11,17210,93310,6468,45711,28715,82413,371
Revenue growth-3.3%-0.5%+20.9%-29.5%-15.5%+9.7%+8.4%
EBITDA3,0752,5582,2241,4901,3994,1202,698
EBITDA margin+27.5%+23.4%+20.9%+17.6%+12.4%+26.0%+20.2%
Profit before tax3,1642,3582,4571,6161,6374,1932,370
Net profit2,4271,7371,9511,2171,5363,1131,879
Net profit margin+21.7%+15.9%+18.3%+14.4%+13.6%+19.7%+14.1%
EPS (₹)41.5830.0833.3520.9424.8353.1332.03
Balance sheet
Total assets27,07625,23422,63022,32419,01719,95216,837
Net worth22,71820,53419,72318,03417,11715,92513,052
Total debt4,2854,6472,8614,2031,8954,0283,741
Cash & bank16229894.3437350.7838686.16
Net working capital5,1965,5124,8347,4477,4889,4458,646
Cash flow
Cash from operations2,9331,6461,7151,8163,7272,9942,201
Cash from investing(1,996)(2,050)(152)(3,230)(1,615)(2,650)(948)
Cash from financing(1,072)616(1,837)1,719(2,448)(27.94)(1,255)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,8002,7872,7472,7902,8482,7322,9172,825
Revenue growth (YoY)-1.4%+0.9%-5.5%+0.1%+16.4%-5.1%+8.3%+4.1%
Other income24221413016083.7711454.26123
Total expenses1,9172,0051,9752,0652,0522,1352,2032,104
EBITDA882781772725796597713721
EBITDA margin+31.7%+28.4%+28.3%+26.3%+28.2%+21.9%+24.7%+26.1%
Depreciation68.9971.9371.9271.4970.0293.8868.2868.16
Interest47.0747.2748.4357.4560.0061.0966.1951.63
Profit before tax1,008876782755750556633724
Tax271184200174191147161186

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 02 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue9,1508,8538,6468,2867,8688,3827,9797,796
Revenue growth (YoY)+16.9%+4.4%+9.0%+7.7%+4.5%+11.9%+8.6%+6.9%
Other income264117188122107135159136
EBITDA1,8391,7501,7081,6781,6031,7601,5781,566
EBITDA margin+20.2%+20.0%+19.9%+20.4%+20.6%+21.0%+20.0%+20.5%
Depreciation487479465429406444419382
Interest10298.2192.7795.2497.75115118113
Profit before tax1,5151,2911,3391,2761,2071,3351,2001,207
Tax483370429428383432354391
Net profit1,032921910848824903846817
EPS (₹)17.8615.8615.6714.6114.2015.5614.5614.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue33,65331,72429,00224,85523,45524,77523,099
Revenue growth+6.8%+7.7%+10.5%+9.3%-3.0%+9.1%+16.4%
Other income4946225572914363,630192
Total expenses26,87325,17323,36821,14819,34419,93218,276
Employee cost5,1904,4763,9233,5223,4513,5353,219
EBITDA6,7806,5515,6343,7074,1124,8434,823
EBITDA margin+20.2%+20.7%+19.4%+14.9%+17.5%+19.6%+20.9%
Depreciation1,7781,6491,5221,2451,1271,055967
Interest38445729014048.6474.49305
Profit before tax5,1125,0664,3802,6123,3737,3443,743
Tax1,6091,5831,2116857262,010899
Net profit3,5633,4533,2731,9202,7573,4102,865
Net profit margin+10.6%+10.9%+11.3%+7.7%+11.8%+13.8%+12.4%
EPS (₹)60.3460.0254.1632.9045.2091.0548.56
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital62.6360.3558.5958.5958.5958.5958.59
Reserves & surplus37,83332,59529,78426,78124,51721,87116,766
Shareholders' funds (net worth)37,89632,65629,84326,84024,57621,93016,825
Minority interest(8.16)(6.39)8.0012.00(1.93)(0.88)0.14
Secured loans4,1193,9553,9682,5575441,0541,315
Unsecured loans3,9494,3062,6792,7292,3084,2864,511
Total debt8,0688,2616,6485,2862,8515,3395,826
Total liabilities47,13441,26136,77632,35227,63827,51922,813
Assets
Gross block29,25124,46323,44818,59315,52513,61312,441
Net block17,40714,79414,49311,02410,5329,3749,396
Capital work in progress5,2144,9003,8695,3903,7473,0621,986
Investments1,051252372543997591555
Inventories12,05310,5449,8108,5167,5599,0417,700
Sundry debtors7,0945,7464,8174,4664,0123,5034,315
Cash & bank balances9,8708,2356,2786,0844,1905,4742,842
Loans & advances2,9442,6372,8182,2471,9881,6601,555
Total current assets31,96227,16223,72421,31417,74919,67816,412
Total current liabilities11,0628,2207,9417,1535,8785,7755,823
Net working capital20,90018,94215,78214,16111,87113,90310,590
Total assets47,13441,26136,77632,35227,63827,51922,813
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash5,5643,3854,3924,1635,3272,7691,876
Net cash from operating activities5,5263,9252,4352,3875,0163,3294,381
Net cash from investing activities(2,630)(1,866)(4,242)(3,971)(3,211)597(1,563)
Net cash from financing activities(1,269)1208001,814(2,969)(1,365)(1,947)
Net change in cash1,6282,178(1,007)230(1,164)2,561871
Closing cash9,8708,2356,2786,0844,1905,4742,842
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+6.1%+9.4%+16.7%+6.0%-5.3%+7.3%+18.1%
EBITDA growth+3.5%+16.3%+52.0%-9.8%-15.1%+0.4%+24.8%
PBT growth+0.9%+15.7%+67.7%-22.5%-54.1%+96.2%+21.1%
Net income growth+3.2%+5.5%+70.5%-30.4%-19.2%+19.0%+17.9%
Revenue CAGR (3Y)+10.6%+10.6%+5.4%+2.5%+6.2%+14.6%+15.7%
EBITDA CAGR (3Y)+22.3%+16.8%+5.2%-8.4%+2.1%+8.7%+12.0%
Profitability & leverage
Net income margin+10.4%+11.0%+10.9%+7.8%+11.3%+21.5%+12.3%
Return on capital employed+12.4%+14.2%+13.5%+9.2%+12.4%+18.3%+18.5%
Return on net worth+9.9%+11.2%+11.2%+7.5%+11.4%+17.6%+18.5%
Debt / equity0.230.240.210.160.180.290.42
Long-term debt / equity0.040.070.060.030.020.020.01
Interest cover7.689.337.045.711.631.977.91
Efficiency & per share
Fixed asset turnover1.251.321.381.461.611.902.01
Inventory turnover2.983.123.173.092.832.963.09
Debtors turnover5.246.016.255.866.246.345.98
EPS (₹)60.3460.0254.1632.9045.2091.0548.56
Dividend per share (₹)4.000.004.507.509.004.003.00
Book value per share (₹)652.39562.21509.35458.10419.46374.29287.16
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,8002,7872,7472,7902,8482,7322,9172,825
Revenue growth (YoY)-1.4%+0.9%-5.5%+0.1%+16.4%-5.1%+8.3%+4.1%
Other income24221413016083.7711454.26123
Total expenses1,9172,0051,9752,0652,0522,1352,2032,104
EBITDA882781772725796597713721
EBITDA margin+31.7%+28.4%+28.3%+26.3%+28.2%+21.9%+24.7%+26.1%
Depreciation68.9971.9371.9271.4970.0293.8868.2868.16
Interest47.0747.2748.4357.4560.0061.0966.1951.63
Profit before tax1,008876782755750556633724
Tax271184200174191147161186
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue11,17210,93310,6468,45711,28715,82413,371
Revenue growth-3.3%-0.5%+20.9%-29.5%-15.5%+9.7%+8.4%
Other income588328670444671590389
Total expenses8,0978,3768,4226,9679,88811,70410,673
Employee cost1,1611,0639818911,6001,7351,577
EBITDA3,0752,5582,2241,4901,3994,1202,698
EBITDA margin+27.5%+23.4%+20.9%+17.6%+12.4%+26.0%+20.2%
Depreciation285297255243415488473
Interest21323018374.5816.9428.68243
Profit before tax3,1642,3582,4571,6161,6374,1932,370
Tax7496125033891831,080493
Net profit2,4271,7371,9511,2171,5363,1131,879
Net profit margin+21.7%+15.9%+18.3%+14.4%+13.6%+19.7%+14.1%
EPS (₹)41.5830.0833.3520.9424.8353.1332.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital58.0858.0858.5958.5958.5958.5958.59
Reserves & surplus22,66020,47619,66417,97517,05915,86612,994
Shareholders' funds (net worth)22,71820,53419,72318,03417,11715,92513,052
Secured loans1,9061,8421,4321,9232898421,314
Unsecured loans2,3802,8041,4292,2801,6063,1862,427
Total debt4,2854,6472,8614,2031,8954,0283,741
Total liabilities27,07625,23422,63022,32419,01719,95216,837
Assets
Gross block4,6334,2314,0436,2155,7256,8206,181
Net block2,5442,3372,4193,6883,5864,4724,418
Capital work in progress22987.53133239225735815
Investments17,56215,21013,3938,1056,5845,0102,527
Inventories2,3612,3592,3684,1253,3564,8414,360
Sundry debtors4,2104,1953,7774,5603,9735,9285,785
Cash & bank balances16229894.3437350.7838686.16
Loans & advances5638371,0019062,4551,0931,058
Total current assets7,2967,6897,2399,9659,83512,24911,288
Total current liabilities2,1002,1782,4062,5182,3472,8032,642
Net working capital5,1965,5124,8347,4477,4889,4458,646
Total assets27,07625,23422,63022,32419,01719,95216,837
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash29583.3235751.1338467.3568.70
Net cash from operating activities2,9331,6461,7151,8163,7272,9942,201
Net cash from investing activities(1,996)(2,050)(152)(3,230)(1,615)(2,650)(948)
Net cash from financing activities(1,072)616(1,837)1,719(2,448)(27.94)(1,255)
Net change in cash(135)212(274)306(335)316(1.35)
Closing cash16229894.3437350.7838686.16
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+2.2%+2.7%+25.9%-25.1%-28.7%+18.4%+9.1%
EBITDA growth+20.2%+15.0%+49.3%+6.5%-66.1%+52.7%+12.0%
PBT growth+34.1%-4.0%+52.1%-1.3%-61.0%+76.9%+20.6%
Net income growth+39.7%-11.0%+60.3%-20.8%-50.7%+65.7%+22.2%
Revenue CAGR (3Y)+9.7%-1.1%-12.4%-14.2%-2.7%+15.5%+11.7%
EBITDA CAGR (3Y)+27.3%+22.3%-18.6%-18.0%-16.6%+15.6%+4.4%
Profitability & leverage
Net income margin+21.6%+16.0%+18.4%+14.5%+12.9%+19.7%+14.0%
Return on capital employed+12.9%+10.8%+11.7%+8.2%+8.5%+23.0%+16.0%
Return on net worth+11.2%+8.7%+10.4%+7.0%+8.8%+21.5%+15.4%
Debt / equity0.210.190.190.170.180.270.34
Long-term debt / equity0.010.010.000.000.000.000.00
Interest cover7.6410.189.275.981.720.7910.94
Efficiency & per share
Fixed asset turnover2.522.642.081.421.802.432.30
Inventory turnover4.734.633.282.262.753.443.21
Debtors turnover2.662.742.551.982.282.702.43
EPS (₹)41.5830.0833.3520.9424.8353.1332.03
Dividend per share (₹)4.000.004.507.509.004.003.00
Book value per share (₹)391.14353.55336.62307.80292.15271.80222.78
Want more history and ratios?
You're viewing the latest exchange-filed financials for Aurobindo Pharma LTD. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Aurobindo Pharma LTD

Shareholding for the quarter ended Sep 2026: promoters hold 51.90%, foreign institutional investors hold 16.40%, domestic institutional investors hold 25.10% and retail and other public shareholders hold 6.60%.

Promoters: 51.90%DII (Domestic Institutional): 25.10%FII (Foreign Institutional): 16.40%Retail & Others: 6.60%
Sep 2026
QUARTER
51.90% Promoters
25.10% DII (Domestic Institutional)
16.40% FII (Foreign Institutional)
6.60% Retail & Others
Promoter holding - history
Now 51.90% · Sep 2026High 51.90% · Sep 2026Low 51.80% · Dec 2025
50%50.8%51.5%52.3%53%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 51.80%Mar 2026: 51.80%Jun 2026: 51.80%Sep 2026: 51.90%51.80%51.90%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters51.90%51.80%51.80%51.80%
Public48.10%48.20%48.20%48.20%

Group Structure of Aurobindo Pharma LTD

Aurobindo Pharma has 17 subsidiary companies, 2 joint ventures, and 2 associated companies. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

17
Subsidiary companies
2
Joint ventures
2
Associated companies
Key Subsidiaries
Company NameCINShares Held
Aurobindo Antibiotics Private LimitedU24110AP2020PTC115965-
Curateq Biologics Private LimitedU24110TG2020PTC140190-
Auroactive Pharma Private LimitedU24230TG2020PTC138313-
Theranym Biologics Private LimitedU24230TG2022PTC166946-
Auro Peptides LimitedU24232TG2012PLC078350-
Apl Healthcare LimitedU24239TG2006PLC052053-

Showing major subsidiaries. Total: 17.

Charges & Borrowings of Aurobindo Pharma

Open charges
₹2,000 Cr
Satisfied charges
₹4,387.54 Cr
Breakdown by lending institutions
State Bank of India₹2,000.00 Cr
Latest charge details
DateLenderAmountStatus
05 Jun 1997State Bank of India₹2,000 CrOpen
08 Jan 2013Dbs Bank Ltd₹164 CrSatisfied
25 May 2012Ifci Limited₹156 CrSatisfied
25 May 2012Ifci Limited₹130 CrSatisfied
28 Feb 2011Axis Bank Limited₹37.98 CrSatisfied

Total charge records: 44 View all charges

Employees and EPFO Compliance at Aurobindo Pharma

Aurobindo Pharma LTD has a workforce of 15,925 employees as of Aug 07, 2024.

Employee count
15,925
Active EPFO establishments
11
Employee growth
-3.17%
Premium access

Employee and EPFO history for Aurobindo Pharma LTD

Monthly headcount, contribution history and filing status are in the company report.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Aurobindo Pharma

Premium access

GST registrations and filing compliance for Aurobindo Pharma LTD

State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Aurobindo Pharma

Premium access

Credit ratings, litigation, and regulatory alerts for Aurobindo Pharma LTD

Credit ratings, court records and regulatory alerts are in the company report.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Aurobindo Pharma

Premium access

MSME payment history for Aurobindo Pharma LTD

Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Aurobindo Pharma

Premium access

Corporate group structure for Aurobindo Pharma LTD

Parent, subsidiary, associate and joint venture records with holdings are in the company report.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Aurobindo Pharma

Premium access

MCA filings and documents for Aurobindo Pharma LTD

Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Aurobindo Pharma

Directors
09 Feb 2026
Punita Kumar Sinha was appointed as a Director on 09 Feb 2026 & has been associated with this company since 7 months 24 days.
Activity
10 Sep 2025
Aurobindo Pharma Ltd last Annual general meeting of members was held on 10 Sep 2025 as per latest MCA records.
Activity
31 Mar 2025
Aurobindo Pharma Ltd has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Directors
01 Apr 2024
Mangalam Ramasubramanian Kumar was appointed as a Director on 01 Apr 2024 & has been associated with this company since 2 years 6 months.
Directors
09 Nov 2023
Satakarni Makkapati was appointed as a Director on 09 Nov 2023 & has been associated with this company since 2 years 10 months.
Charges
22 Feb 2023
A charge with State Bank Of India of Rs. 2,000.00 Cr registered on 05 Jun 1997 with Charge ID 80013576 was modified on 22 Feb 2023.

Recent News on Aurobindo Pharma

Frequently Asked Questions about Aurobindo Pharma LTD

Aurobindo Pharma is an active public limited company in the pharma sector based in Hyderabad, Telangana, India. It was incorporated on 26 December 1986 (40+ years old) and is registered under CIN L24239TG1986PLC015190. Listed on BSE: 524804 and NSE: AUROPHARMA. The company has 15,925 employees.

Aurobindo Pharma reported revenue of ₹33,653 Cr for FY 2025-26 (up 6.08% YoY) based on consolidated financials.

The current directors of Aurobindo Pharma are:

The primary industry of Aurobindo Pharma is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Aurobindo Pharma is listed on both BSE (code: 524804) and NSE (symbol: AUROPHARMA).

Aurobindo Pharma can be reached at the registered office: Plot No.2 Maithrivihar Behind Maithri Vanam Ameerpet, Hyderabad, Telangana, India – 500038, or through the website aurobindo.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available